Halozyme Therapeutics Beats Q4 Views; Outlook Shy Of Consensus

posted better-than expected fourth quarter results on Monday, but offered a revenue forecast shy of analysts' consensus. The San Diego-based drug development company changed hands recently in the extended session at $15.30, up $0.08. For 2015, Halozyme forecast revenue of $85 million to $95 million, versus Wall Street's expectation of $97.7 million. Halozyme also forecast a net cash burn rate of $35 million to $45 million for 2015, and posted cash and cash equivalents as of December 31 of $61.39 million. Halozyme expects first quarter royalty revenues of between $6 million to $7 million, up from $4 million in the fourth quarter. The company's fourth quarter net loss narrowed to $5.3 million, or $0.04 a share, from $22.0 million, or $0.19 a share, last year. Revenue more than doubled to $30.4 million, from $12.5 million. Wall Street expected a loss of $0.07 a share, on revenue of $25.59 million.